The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non‑small‑cell lung cancer

Deng,Yanming; Feng,Weineng; Wu,Jing; Chen,Zecheng; Tang,Yicong; Zhang,Hua; Liang,Jianmiao; Xian,Haibing; Zhang,Shunda

doi:10.3892/mco.2013.190

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non‑small‑cell lung cancer

Authors:
- Yanming Deng
- Weineng Feng
- Jing Wu
- Zecheng Chen
- Yicong Tang
- Hua Zhang
- Jianmiao Liang
- Haibing Xian
- Shunda Zhang
View Affiliations

Affiliations: Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China, Oncology Institution, The First People's Hospital of Foshan, Foshan, Guangdong 528000, P.R. China
Published online on: September 23, 2013 https://doi.org/10.3892/mco.2013.190
Pages: 116-120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been demonstrated that erlotinib is effective in treating patients with brain metastasis from non‑small‑cell lung cancer. However, the number of studies determining the erlotinib concentration in these patients is limited. The purpose of this study was to measure the concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non‑small‑cell lung carcinoma. Six patients were treated with the standard recommended daily dose of erlotinib (150 mg) for 4 weeks. All the patients had previously received chemotherapy, but no brain radiotherapy. At the end of the treatment period, blood plasma and cerebrospinal fluid samples were collected and the erlotinib concentration was determined by high‑performance liquid chromatography‑tandem mass spectrometry (HPLC‑MS̸MS). The average erlotinib concentration in the blood plasma and the cerebrospinal fluid was 717.7±459.7 and 23.7±13.4 ng/ml, respectively. The blood‑brain barrier permeation rate of erlotinib was found to be 4.4±3.2%. In patients with partial response (PR), stable disease (SD) and progressive disease (PD), the average concentrations of erlotinib in the cerebrospinal fluid were 35.5±19.0, 19.1±8.7 and 16.4±5.9 ng/ml, respectively. In addition, the efficacy rate of erlotinib for metastatic brain lesions was 33.3%, increasing to 50% in patients with EGFR mutations. However, erlotinib appeared to be ineffective in cases with wild‑type EGFR. In conclusion, a relatively high concentration of erlotinib was detected in the cerebrospinal fluid of patients with brain metastases from non‑small‑cell lung cancer. Thus, erlotinib may be considered as a treatment option for this patient population.

View Figures

View References

1.	Yamanaka R: Medical management of brain metastases from lung cancer (Review). Oncol Rep. 22:1269–1276. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Mehta MP, Paleologos NA, Mikkelsen T, et al: The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 96:71–83. 2010. View Article : Google Scholar
3.	Gaspar LE, Mehta MP, Patchell RA, et al: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 96:17–32. 2010. View Article : Google Scholar
4.	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Rosell R, Moran T, Queralt C, Porta R, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Bai H and Han B: The effectiveness of erlotinib against brain metastases in non-small-cell lung cancer patients. Am J Clin Oncol. 36:110–115. 2013. View Article : Google Scholar : PubMed/NCBI
7.	Wu YL, Zhou C, Cheng Y, et al: A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT). J Clin Oncol. 29(Suppl 15): abs.76052011.
8.	Porta R, Sánchez-Torres JM, Paz-Ares L, et al: Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 37:624–631. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Park SJ, Kim HT and Lee DH: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 77:556–560. 2012. View Article : Google Scholar
10.	Masuda T, Hattori N, Hamada A, et al: Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 67:1465–1469. 2011. View Article : Google Scholar
11.	Wilson CM, Gaber MW, Sabek OM, et al: Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys. 74:934–941. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Zhang W, Siu LL, Moore MJ and Chen EX: Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 814:143–147. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Abbott NJ, Rönnbäck L and Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 7:41–53. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Deeken JF and Loscher W: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 13:1663–1674. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Weber B, Winterdahl M, Memon A, et al: Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 6:1287–1289. 2011. View Article : Google Scholar
16.	Togashi Y, Masago K, Masuda S, et al: Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 70:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Togashi Y, Masago K, Fukudo M, et al: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 5:950–955. 2010.PubMed/NCBI
18.	Zhao J, Chen M, Zhong W, Zhang L, et al: Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 14:188–193. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:3267–3279. 2001.PubMed/NCBI
20.	Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2240–2250. 2002. View Article : Google Scholar
21.	Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 99:283–286. 2010. View Article : Google Scholar
22.	Lind JS, Lagerwaard FJ, Smit EF, et al: Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 74:1391–1396. 2009. View Article : Google Scholar : PubMed/NCBI